Getinge AB Ser. B(GETIb.ST), Friday delivered a strong Q2, with net sales up 4.1 percent organically and order intake rising 4.4 percent, despite headwinds from tariffs and currency fluctuations, CEO Mattias Perjos reported.
Adjusted gross profit climbed to SEK 4,183 million and adjusted EBITA reached SEK 989 million, even as tariffs shaved SEK 270 million from results.
The Acute Care Therapies division saw sustained ventilator demand and high ECLS consumable orders, while Sterile Transfer life-science sales accelerated. Bio-Processing rationalization prepares Getinge for future growth. Paragonix, acquired in late 2024, set a new sales record and boosted EBITA earlier than expected.
A Zimmer Biomet partnership expands Surgical Workflows into U.S. ASCs. Free cash flow totaled SEK 510 million.
GETIb.ST is currently trading at SEK 201.90, up 6.60 percent or SEK 12.50 on the Stockholm.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.